News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,396 Results
Type
Article (17675)
Company Profile (120)
Press Release (166601)
Section
Business (58674)
Career Advice (945)
Deals (9462)
Drug Delivery (36)
Drug Development (23510)
Employer Resources (71)
FDA (2373)
Job Trends (4269)
News (92910)
Policy (5848)
Tag
2024 BioCapital Digital (3)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (490)
Accelerated approval (1)
Adcomms (13)
Allergies (19)
Alliances (16345)
ALS (33)
Alzheimer's disease (434)
Antibody-drug conjugate (ADC) (73)
Approvals (2340)
Artificial intelligence (99)
Autoimmune disease (9)
Automation (4)
Bankruptcy (82)
Best Places to Work (2920)
BIOSECURE Act (18)
Biosimilars (25)
Biotechnology (111)
Bladder cancer (24)
Brain cancer (14)
Breast cancer (81)
Cancer (766)
Cardiovascular disease (52)
Career advice (761)
Career pathing (19)
CAR-T (90)
Cell therapy (251)
Cervical cancer (6)
Clinical research (18676)
Collaboration (393)
Compensation (92)
Complete response letters (11)
COVID-19 (747)
CRISPR (16)
C-suite (127)
Cystic fibrosis (40)
Data (645)
Denatured (5)
Depression (19)
Diabetes (58)
Diagnostics (1084)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (21)
Drug discovery (62)
Drug pricing (22)
Drug shortages (2)
Duchenne muscular dystrophy (32)
Earnings (15948)
Editorial (16)
Employer branding (8)
Employer resources (69)
Events (31494)
Executive appointments (333)
FDA (2648)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (332)
Gene editing (47)
Generative AI (12)
Gene therapy (172)
GLP-1 (261)
Government (628)
Grass and pollen (1)
Guidances (9)
Healthcare (2461)
Huntington's disease (18)
IgA nephropathy (11)
Immunology and inflammation (60)
Indications (11)
Infectious disease (801)
Inflammatory bowel disease (67)
Inflation Reduction Act (3)
Influenza (19)
Intellectual property (38)
Interviews (138)
IPO (4139)
IRA (13)
Job creations (1476)
Job search strategy (704)
Kidney cancer (4)
Labor market (20)
Layoffs (160)
Leadership (11)
Legal (1200)
Liver cancer (17)
Lung cancer (89)
Lymphoma (57)
Machine learning (2)
Management (23)
Manufacturing (134)
MASH (23)
Medical device (727)
Medtech (728)
Mergers & acquisitions (5510)
Metabolic disorders (215)
Multiple sclerosis (30)
NASH (8)
Neurodegenerative disease (43)
Neuropsychiatric disorders (13)
Neuroscience (640)
NextGen: Class of 2025 (1481)
Non-profit (492)
Northern California (841)
Now hiring (16)
Obesity (119)
Opinion (174)
Ovarian cancer (29)
Pain (30)
Pancreatic cancer (24)
Parkinson's disease (46)
Partnered (8)
Patents (70)
Patient recruitment (27)
Peanut (12)
People (22250)
Pharmaceutical (15)
Phase I (7245)
Phase II (8918)
Phase III (5022)
Pipeline (378)
Podcasts (29)
Policy (53)
Postmarket research (306)
Preclinical (2930)
Press Release (63)
Prostate cancer (28)
Psychedelics (18)
Radiopharmaceuticals (82)
Rare diseases (167)
Real estate (2453)
Recruiting (36)
Regulatory (4542)
Reports (18)
Research institute (527)
Resumes & cover letters (152)
RNA editing (2)
RSV (13)
Schizophrenia (23)
Series A (77)
Series B (39)
Service/supplier (6)
Sickle cell disease (22)
Southern California (783)
Special edition (10)
Sponsored (11)
Startups (1790)
State (1)
Stomach cancer (5)
Supply chain (20)
The Weekly (24)
United States (6990)
Vaccines (220)
Venture capitalists (30)
Webinars (9)
Weight loss (84)
Women's health (9)
Worklife (6)
Date
Today (41)
Last 7 days (251)
Last 30 days (1141)
Last 365 days (12508)
2025 (2494)
2024 (12749)
2023 (13342)
2022 (16151)
2021 (17029)
2020 (13265)
2019 (9687)
2018 (7718)
2017 (9038)
2016 (8194)
2015 (9492)
2014 (9758)
2013 (9496)
2012 (6126)
2011 (6505)
2010 (5885)
Location
Africa (329)
Alabama (26)
Alaska (3)
Arizona (42)
Arkansas (2)
Asia (13871)
Australia (2681)
California (1975)
Canada (657)
China (182)
Colorado (38)
Connecticut (82)
Delaware (35)
Europe (30234)
Florida (212)
Georgia (30)
Idaho (13)
Illinois (128)
India (10)
Indiana (101)
Iowa (2)
Japan (51)
Kansas (16)
Kentucky (4)
Louisiana (3)
Maine (2)
Maryland (302)
Massachusetts (1556)
Michigan (72)
Minnesota (111)
Missouri (15)
Montana (8)
Nebraska (4)
Nevada (8)
New Hampshire (6)
New Jersey (533)
New Mexico (11)
New York (524)
North Carolina (340)
North Dakota (4)
Northern California (841)
Ohio (51)
Oklahoma (6)
Oregon (8)
Pennsylvania (412)
Puerto Rico (2)
Rhode Island (8)
South America (405)
South Carolina (2)
Southern California (783)
Tennessee (19)
Texas (229)
Utah (27)
Virginia (14)
Washington D.C. (16)
Washington State (313)
Wisconsin (11)
184,396 Results for "nanjing legend biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
Johnson & Johnson and Legend Biotech hope to hit blockbuster status for Carvykti this year.
March 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
March 12, 2025
·
18 min read
Press Releases
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
February 25, 2025
·
1 min read
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.
December 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 20, 2024
·
1 min read
Pharm Country
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
Legend Biotech Corporation today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
May 29, 2024
·
1 min read
Business
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
Legend Biotech Corporation, a global leader in cell therapy, reported its first quarter 2024 unaudited financial results and key corporate highlights.
May 13, 2024
·
11 min read
Press Releases
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
November 5, 2024
·
4 min read
Drug Development
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients.
June 3, 2024
·
31 min read
Pharm Country
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
April 11, 2024
·
1 min read
1 of 18,440
Next
